Modern possibilities of organ-preserving treatment of patients with muscle-invasive bladder cancer

Cover Page

Cite item

Full Text

Abstract

The article reviews the current trends in the organ-preserving treatment of patients with muscular-invasive bladder cancer. An historical insight into the treatment tactics for this malignant disease included. The current trends in the use of surgical technology, radiation therapy, chemotherapy and immunotherapy, as well as molecular genetic diagnostic in patients with invasive bladder carcinomas are demonstrated. Due to the lack of randomized studies we are not able to use such organ-preserving techniques into practice, but it allows to performthis approach in carefully selected groups of patients.

About the authors

Vladimir J. Startsev

Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of Russian Federation

Author for correspondence.
Email: doc.urolog@gmail.com

Doctor of Medical Science, Professor of the Department of Oncology, Pediatric Oncology and Radiation Therapy

Russian Federation, Saint-Petersburg

Ivan N. Dilenok

Crimean Republican Oncological Clinical Dispensary named after V.M. Efetov

Email: ivan_dylenok@mail.ru

Head of Urological Department

Russian Federation, Simferopol

Timur R. Dzhemilev

Crimean Republican Oncological Clinical Dispensary named after V.M. Efetov

Email: rumit_68@mail.ru

врач-уролог отделения урологии

Russian Federation, Simferopol

References

  1. Gschwend JE, Fair WR, Vieweg J. Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. Eur Urol. 2000;38(2):121-130. https://doi.org/10.1159/000020268.
  2. Khalil el SA. Long term complications following ileal conduit urinary diversion after radical cystectomy. J Egypt Natl Canc Inst. 2010;22(1):13-18.
  3. El-Taji OM, Khattak AQ, Hussain SA. Bladder reconstruction: The past, present and future. Oncol Lett. 2015;10(1):3-10. https://doi.org/10.3892/ol.2015.3161.
  4. Sauer R, Birkenhake S, Kühn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;40(1):121-127. https://doi.org/10.1016/s0360-3016(97)00579-8.
  5. Huddart RA, Hall E, Lewis R, et al. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int. 2010;106(6):753-755. https://doi.org/10.1111/j.1464-410X.2010.09537.x.
  6. Shipley W, Zietman A, Kaufman D, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates? The Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol. 2005;15(1):36-41. https://doi.org/10.1016/j.semradonc.2004.07.008.
  7. Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Crit Rev Oncol Hematol. 2015;95(3):387-396. https://doi.org/10.1016/j.critrevonc.2015.04.006.
  8. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801-3809. https://doi.org/10.1200/JCO.2014.57.5548.
  9. El-Taji OM, Alam S, Hussain SA. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. Curr Treat Options Oncol. 2016;17(3):15. https://doi.org/10.1007/s11864-016-0390-8.
  10. nccn.org [Internet]. NCCN Clinical Practice Guidelines in Oncology [cited 1 Apr 2019]. Available from: www.nccn.org/professionals/physicians_gls.
  11. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778-792. https://doi.org/10.1016/j.eururo.2013.11.046.
  12. Jenkins BJ, Caulfield MJ, Fowler CG, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol. 1988;62(4):343-346. https://doi.org/10.1111/j.1464-410X.1988.tb04362.x
  13. Skinner EC. Treatment of muscle-invasive bladder cancer in older patients. Am Soc Clin Oncol Educ Book. 2016;35: e228-233. https://doi.org/10.14694/EDBK_158974.
  14. Koga F, Kihara K. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol. 2012;19(5):388-401. https://doi.org/10.1111/j.1442-2042.2012.02974.x.
  15. Walker M, French SD, Doiron RC, et al. Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers. Radiother Oncol. 2017;125(2):351-356. https://doi.org/10.1016/j.radonc.2017.08.036.
  16. Jensen TK, Jensen NV, Jorgensen SM, et al. Trends in cancer of the urinary bladder and urinary tract in elderly in Denmark, 2008-2012. Acta Oncol. 2016;55 Suppl 1:85-90. https://doi.org/10.3109/0284186X.2015.1115122.
  17. Poletajew S, Biernacki R, Buraczynski P, et al. Patterns of care in patients with muscle-invasive bladder cancer – a retrospective cohort study. Contemp Oncol (Pozn). 2016;20(4):341-343. https://doi.org/10.5114/wo.2016.61857.
  18. Clayman RH, Shipley WU, Galland-Girodet S, et al. Outcomes of selective bladder preservation in the elderly treated with conservative surgery and chemoradiation. Int J Radiat Oncol Biol Phys. 2013;87(2):S83. https://doi.org/10.1016/j.ijrobp.2013.06.216.
  19. Erlich A, Zlotta AR. Treatment of bladder cancer in the elderly. Investig Clin Urol. 2016;57 Suppl 1: S 26-35. https://doi.org/10.4111/icu.2016.57.S 1.S 26.
  20. Byun SJ, Kim JH, Oh YK, Kim BH. Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. Radiat Oncol J. 2015;33(4):294-300. https://doi.org/10.3857/roj.2015.33.4.294.
  21. Grubmueller B, Seitz C, Shariat SF. The treatment of muscle-invasive bladder cancer in geriatric patients. Curr Opin Urol. 2016;26(2):160-164. https://doi.org/10.1097/MOU.0000000000000262.
  22. Lyons MD, Smith AB. Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer. Urol Oncol. 2016;34(6):262-270. https://doi.org/10.1016/j.urolonc.2015.11.023.
  23. Startsev VY. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences. Arch Ital Urol Androl. 2002;74(2):54-56.
  24. Solsona E, Iborra I, Collado A, et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 2010;184(2):475-480. https://doi.org/10.1016/j.juro.2010.04.008.
  25. Garcia MM, Gottschalk AR, Brajtbord J, et al. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014;9(3):e89754. https://doi.org/10.1371/journal.pone.0089754.
  26. Abufaraj M, Gust K, Moschini M, et al. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Transl Androl Urol. 2016;5(5):735-744. https://doi.org/10.21037/tau.2016.08.23.
  27. Moschini M, Luzzago S, Zaffuto E, et al. The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. Eur J Surg Oncol. 2017;43(4):808-814. https://doi.org/10.1016/j.ejso.2016.08.024.
  28. Riou O, Chauvet B, Lagrange JL, et al. [Radiotherapy of bladder cancer]. Cancer Radiother. 2016;20 Suppl:S 196-199. https://doi.org/10.1016/j.canrad.2016.07.010.
  29. Kibrom AZ, Knight KA. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice. J Med Radiat Sci. 2015;62(4):277-285. https://doi.org/10.1002/jmrs.129.
  30. Hafeez S, Warren-Oseni K, McNair HA, et al. Prospective study delivering simultaneous integrated high-dose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016;94(5):1022-1030. https://doi.org/10.1016/j.ijrobp.2015.12.379.
  31. Lutkenhaus LJ, van Os RM, Bel A, Hulshof MC. Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. Radiat Oncol. 2016;11:45. https://doi.org/10.1186/s13014-016-0618-6.
  32. Hoskin P, Rojas A, Saunders M. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study. Int J Radiat Oncol Biol Phys. 2009;73(5):1425-1431. https://doi.org/10.1016/j.ijrobp.2008.06.1950.
  33. Nowak-Sadzikowska J, Skora T, Szyszka-Charewicz B, Jakubowicz J. Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy. Rep Pract Oncol Radiother. 2016;21(1):31-36. https://doi.org/10.1016/j.rpor.2015.09.001.
  34. Болотина Л.В., Королева Л.А. Современные подходы к лекарственной терапии рака мочевого пузыря после первого прогрессирования // Исследования и практика в медицине. – 2015. – Т. 2. – № 2. – С. 29–34. [Bolotina LV, Koroleva LA. Modern approaches to drug therapy of bladder cancer after first progression. Issledovaniya i praktika v meditsine. 2015;2(2):29-34. (In Russ.)]
  35. Rose TL, Milowsky MI. Improving Systemic Chemotherapy for Bladder Cancer. Curr Oncol Rep. 2016;18(5):27. https://doi.org/10.1007/s11912-016-0512-2.
  36. Pokuri VK, Syed JR, Yang Z, et al. Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Clin Genitourin Cancer. 2016;14(1): e59-65. https://doi.org/10.1016/j.clgc.2015.09.013.
  37. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011;22(1):139-144. https://doi.org/10.1093/annonc/mdq333.
  38. Guancial EA, Kilari D, Xiao GQ, et al. Platinum concentration and pathologic response to cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer. PLoS One. 2016;11(5): e0155503. https://doi.org/10.1371/journal.pone.0155503.
  39. Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68(6):959-967. https://doi.org/10.1016/j.eururo.2015.07.009.
  40. Xylinas E, Hassler MR, Zhuang D, et al. An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer. Biomolecules. 2016;6(3). https://doi.org/10.3390/biom6030037.
  41. Sidaway P. Bladder cancer: Targeted agents reverse chemotherapy resistance in urothelial carcinoma. Nat Rev Urol. 2016;13(9):494. https://doi.org/10.1038/nrurol.2016.138.
  42. Sideris S, Aoun F, Zanaty M, et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol. 2016;4(6):1063-1067. https://doi.org/10.3892/mco.2016.821.
  43. Кулева С.А., Семиглазова Т.Ю., Звягинцева Д.А., и др. Cardiovascular complications of antineoplastic therapy in children // Педиатр. – 2017. – Т. 8. – № 3. – С. 130–141. [Kuleva SA, Semiglazova TY, Zvyagintseva DA, et al. Kardiovaskulyarnaya toksichnost’ protivoopukholevogo lecheniya u detey. Pediatrician (St. Petersburg). 2017;8(3):130-141. (In Russ.)]
  44. Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):49-61. https://doi.org/10.1093/annonc/mdv509.
  45. Terashima Y. CDDP concentration of bladder tumors – comparison between intraarterial infusion and intravenous infusion. Nihon Gan Chiryo Gakkai Shi. 1988;23(4):859-866.
  46. Azuma H, Inamoto T, Takahara K, et al. Novel bladder preservation therapy with Osaka Medical College regimen. J Urol. 2015;193(2):443-450. https://doi.org/10.1016/j.juro.2014.08.094.
  47. Miyata Y, Nomata K, Ohba K, et al. Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients. Eur J Surg Oncol. 2015;41(3):361-367. https://doi.org/10.1016/j.ejso.2014.07.043.
  48. Maebayashi T, Ishibashi N, Aizawa T, et al. Radiotherapy for muscle-invasive bladder cancer in very elderly patients. Anticancer Res. 2016;36(9):4763-4769. https://doi.org/10.21873/anticanres.11033.
  49. Тимофеев Д.А., Генералов М.И., Балахнин П.В., и др. Чрескожно имплантируемые инфузионные системы: расширение возможностей комбинированного лечения рака мочевого пузыря // Онкоурология. – 2009. – № 3. – С. 74–78. [Timofeev DA, Generalov MI, Balakhnin PV, et al. Transcutaneous infusion systems: extension of the capacities of multimodality treatment for urinary bladder cancer. Onkourologiya. 2009;(3):74-78. (In Russ.)]
  50. Горелов А.И., Симбирцев А.С., Журавский Д.А., Горелова А.А. Ингибиторы PD-1/PD-L1 в лечении рака мочевого пузыря: от медиатора иммунного ответа к таргетной терапии // Урологические ведомости. – 2018. – Т. 8. – № 2. – С. 64–72. [Gorelov AI, Simbirtsev AS, Zhuravskii DA, Gorelova AA. A review of the PD-1/PD-l1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment. Urologicheskie vedomosti. 2018;8(2):64-72. (In Russ.)] https://doi.org/10.17816/uroved8264-72.
  51. Zhu HJ, Zhang ZQ, Zeng XF, et al. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer. Cancer Gene Ther. 2004;11(4):263-272. https://doi.org/10.1038/sj.cgt.7700672.
  52. Zhang H, Wang F, Mao C, et al. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells. Int J Radiat Biol. 2017;93(2):174-183. https://doi.org/10.1080/09553002.2017.1231942.
  53. Kotwal S, Choudhury A, Johnston C, et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys. 2008;70(2):456-463. https://doi.org/10.1016/j.ijrobp.2007.06.030.
  54. Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120-137. https://doi.org/10.1016/j.eururo.2014.02.038.
  55. Mathieu R, Lucca I, Klatte T, et al. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy? Curr Opin Urol. 2015;25(5):476-482. https://doi.org/10.1097/MOU.0000000000000203.
  56. Gerardi MA, Jereczek-Fossa BA, Zerini D, et al. Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. Ecancer medical science. 2016;10:657. https://doi.org/10.3332/ecancer.2016.657.
  57. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol. 2017;35(20):2299-2305. https://doi.org/10.1200/JCO.2016.69.2327.
  58. Rodel C, Weiss C. Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence? J Clin Oncol. 2014;32(34):3787-3788. https://doi.org/10.1200/JCO.2014.58.5521.
  59. Smith ZL, Christodouleas JP, Keefe SM, et al. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013;112(1):13-25. https://doi.org/10.1111/j.1464-410X.2012.11762.x.
  60. Milowsky MI, Rumble RB, Booth CM, et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34(16):1945-1952. https://doi.org/10.1200/JCO.2015.65.9797.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Overall survival of patients with muscular-invasive bladder cancer considering tumor grade

Download (82KB)
Indexing metadata
3. Fig. 2. Overall survival of patients with muscle-invasive bladder cancer after conservative treatment

Download (95KB)
Indexing metadata

Copyright (c) 2019 Startsev V.J., Dilenok I.N., Dzhemilev T.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies